Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of Daiichi Sankyo Company, Ltd, announced today that it will merge with its US-based sister company, Asubio Pharmaceuticals, Inc.  As a result, Asubio Pharmaceuticals, Inc. projects will be integrated into the Daiichi Sankyo global development organization, led by Mahmoud Ghazzi, MD, PhD.

Asubio Pharmaceuticals' parent company, Asubio Pharma Co., Ltd, which is based in Japan, will continue to operate as a wholly owned subsidiary of Daiichi Sankyo Co., Ltd., with a focus on discovery research.

Asubio Pharmaceuticals, Inc.'s ongoing clinical trial in patients with acute spinal cord injury, ASBI 603ASCENT Study (SUN13837) has completed enrollment.  An analysis and dissemination of the data will be managed by Daiichi Sankyo. 

"In line with the Daiichi Sankyo five-year business plan to optimize our business of delivering innovative treatments to patients, consolidating the current Asubio US projects under the company's overall R&D organization helps us streamline our operations," said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Company, Ltd., and Executive Chairman and President, Daiichi Sankyo, Inc.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model," to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/daiichi-sankyo-inc-and-asubio-pharmaceuticals-inc-merge-300057791.html

SOURCE Daiichi Sankyo, Inc.

Copyright 2015 PR Newswire